Literature DB >> 1687479

Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues.

H Kikkawa1, K Naito, K Ikezawa.   

Abstract

Tracheal relaxing effects and beta 2-selectivity of TA-2005 were investigated by functional experiments and radioligand binding assay in guinea pigs in comparison with those of other beta-agonists, isoproterenol, procaterol, formoterol and salbutamol. The relaxing activity of TA-2005 on histamine-induced contraction in the isolated trachea was most potent among the five agonists, and it was blocked by a beta 2-selective antagonist (ICI 118,551) but not by a beta 1-selective antagonist (bisoprolol). The potency of the relaxing effect was in the order of TA-2005 (pD2 = 9.79) greater than formoterol greater than procaterol greater than isoproterenol greater than or equal to salbutamol. The positive chronotropic effect of TA-2005 was similar to that of isoproterenol; and it was more potent than those of formoterol, procaterol and salbutamol in the isolated atria. The selectivity for tracheal muscle to atria of these agonists were in the order of procaterol greater than greater than or equal to formoterol greater than TA-2005 greater than salbutamol much greater than isoproterenol. A radioligand binding experiment using guinea pig lung and cardiac ventricle as beta 2- and beta 1-adrenoceptor sources, respectively, has also demonstrated that TA-2005 possesses extremely high affinity (IC50 = 1.04 nM) and selectivity (38-fold) to beta 2-adrenoceptors. By addition of GTP, the competition curve of [125I]iodocyanopindolol shifted rightward, indicating the agonist property. These results confirmed that TA-2005 is a highly beta 2-selective agonist that exerts a potent tracheal relaxing effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687479     DOI: 10.1254/jjp.57.175

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

Review 1.  β(2) -adrenoceptor agonists: current and future direction.

Authors:  Mario Cazzola; Luigino Calzetta; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Roberta Razzetti; Maurizio Civelli; Stefano Bongrani; Ferruccio Berti
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 3.  ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

Authors:  Maria Gabriella Matera; Mario Cazzola
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists.

Authors:  Elizabeth M Rosethorne; Robert J Turner; Robin A Fairhurst; Steven J Charlton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-08       Impact factor: 3.000

5.  Tracheal relaxing effects and beta2 adrenoceptor selectivity of S1319, a novel sponge-derived bronchodilator agent, in isolated guinea-pig tissues.

Authors:  H Suzuki; A Ueno; M Takei; K Sindo; T Miura; M Sakakibara; T Higa; H Fukamachi
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  Homology modeling and flex-ligand docking studies on the guinea pig beta(2) adrenoceptor: structural and experimental similarities/ differences with the human beta(2).

Authors:  Marvin A Soriano-Ursúa; José G Trujillo-Ferrara; José Correa-Basurto
Journal:  J Mol Model       Date:  2009-03-05       Impact factor: 1.810

Review 7.  Novel long-acting bronchodilators for COPD and asthma.

Authors:  M Cazzola; M G Matera
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 8.  Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease.

Authors:  Robert M Burkes; Ralph J Panos
Journal:  J Exp Pharmacol       Date:  2020-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.